Seminars in Nuclear Medicine
Volume 34, Issue 2 , Pages 122-133 , April 2004

Pitfalls and artifacts in 18FDG PET and PET/CT oncologic imaging

  • Gary J.R Cook

      Affiliations

    • Department of Nuclear Medicine and PET, Royal Marsden Hospital, Sutton, Surrey,, UK
    • Corresponding Author InformationAddress reprint requests to G.J.R. Cook, MSc, MD, FRCP, FRCR, Department of Nuclear Medicine, Royal Marsden Hospital, Sutton, Surrey SM2 5PT, UK
    • ,
  • Eva A Wegner

      Affiliations

    • Clinical PET Centre, Guys and St Thomas’ Hospitals, London, United Kingdom UK
    • ,
  • Ignac Fogelman

      Affiliations

    • Clinical PET Centre, Guys and St Thomas’ Hospitals, London, United Kingdom UK

References 

  1. Torizuka T, Tamaki N, Inokuma T, et al.  In vivo assessment of glucose metabolism in hepatocellular carcinoma with FDG-PET. J Nucl Med. 1995;36:1811–1817
  2. Lodge MA, Lucas JD, Marsden PK, et al.  A PET study of 18FDG uptake in soft tissue masses. Eur J Nucl Med. 1999;26:22–30
  3. Cook GJR, Fogelman I, Maisey MN. Normal physiological and benign pathological variants of 18-FDG PET scanning (potential for error in interpretation). Semin Nucl Med. 1996;26:308–314
  4. Cook GJR, Maisey MN, Fogelman I. Normal variants, artefacts and interpretative pitfalls in PET imaging with 18-fluoro-2-deoxyglucose and carbon-11 methionine. Eur J Nucl Med. 1999;26:1363–1378
  5. Shreve PD, Anzai Y, Wahl RL. Pitfalls in oncologic diagnosis with FDG PET imaging (physiologic and benign variants). Radiographics. 1999;19:61–77
  6. Alavi A, Gupta N, Alberini JL, et al.  Positron emission tomography imaging in non-malignant thoracic disorders. Semin Nucl Med. 2002;32:293–321
  7. Hustinx R, Smith RJ, Benard F, et al.  Dual time point fluorine-18 fluorodeoxyglucose positron emission tomography (a potential method to differentiate malignancy from inflammation and normal tissue in the head and neck). Eur J Nucl Med. 1999;26:1345–1348
  8. Franceschi D, Cabahung C, Cohen B, et al.  Variability in FDG uptake in the palantine tonsils. Eur J Nucl Med. 2002;29:S160
  9. Brink I, Reinhardt MJ, Hoegerle S, et al.  Increased metabolic activity in the thymus gland studied with 18F-FDG PET (age dependency and frequency after chemotherapy). J Nucl Med. 2001;42:591–595
  10. Jerusalem G, Beguin Y, Fassotte MF, et al.  Early detection of relapse by whole-body positron emission tomography in the follow-up of patients with Hodgkin’s disease. Ann Oncol. 2003;14:123–130
  11. Fujii H, Ide M, Yasuda S, et al.  Increased FDG uptake in the wall of the right atrium in people who participated in a cancer screening program with whole-body PET. Ann Nucl Med. 1999;13:55–59
  12. Tomemori T, Kitagawa M, Nakahara K, et al.  Factors affecting non-pathological gastric uptake in whole body FDG-PET imaging. Eur J Nucl Med. 2001;28:1080
  13. Qureshy A, Kubota K, Iwata R, et al.  Localization and reduction of FDG intestinal uptake (tissue distribution and autoradiography study). Nucl Med Commun. 2002;23:388
  14. Jadvar H, Schambye RB, Segall GM. Effect of atropine and sincalide on the intestinal uptake of F-18 fluorodeoxyglucose. Clin Nucl Med. 1999;24:965–967
  15. Miraldi F, Vesselle H, Faulhaber PF, et al.  Elimination of artifactual accumulation of FDG in PET imaging of colorectal cancer. Clin Nucl Med. 1998;23:3–7
  16. Cohade C, Osman M, Nakamoto Y, et al.  Initial experience with oral contrast in PET/CT (phantom and clinical studies). J Nucl Med. 2003;44:412–416
  17. Dizendorf EV, Treyer V, Von Schulthess GK, et al.  Application of oral contrast media in coregistered positron emission tomography-CT. AJR Am J Roentgenol. 2002;179:477–481
  18. Kosuda S, Fisher S, Kison PV. Uptake of 2-deoxy-2-[18F]fluoro-D-glucose in the normal testis (retrospective PET study and animal experiment). Ann Nucl Med. 1997;11:195–199
  19. Fenchel S, Grab D, Nuessle K, et al.  Asymptomatic adnexal masses (correlation of FDG PET and histopathologic findings). Radiology. 2002;223:780–788
  20. Chander S, Meltzer CC, McCook BM. Physiologic uterine uptake of FDG during menstruation demonstrated with serial combined positron emission tomography and computed tomography. Clin Nucl Med. 2002;27:22–24
  21. Kao CH. FDG uptake in a huge uterine myoma. Clin Nucl Med. 2003;28:249
  22. Kostakoglu L, Wong JC, Barrington SF, et al.  Speech-related visualization of laryngeal muscles with fluorine-18-FDG. J Nucl Med. 1996;37:1771–1773
  23. Barrington SF, Maisey MN. Skeletal muscle uptake of fluorine-18-FDG (effect of oral diazepam). J Nucl Med. 1996;37:1127–1129
  24. Cohade C, Osman M, Pannu HK, et al.  Uptake in supraclavicular area fat (“USA-Fat”) (description on 18F-FDG PET/CT). J Nucl Med. 2003;44:170–176
  25. Hany TF, Gharehpapagh E, Kamel EM, et al.  Brown adipose tissue (a factor to consider in symmetrical tracer uptake in the neck and upper chest region). Eur J Nucl Med. 2002;29:1393–1398
  26. Locher JT, Frey LD, Seybold K, et al.  Myocardial 18F-FDG-PET. Experiences with the euglycemic hyperinsulinemic clamp technique. Angiology. 1995;46:313–320
  27. Martin WH, Jones RC, Delbeke D, et al.  A simplified intravenous glucose loading protocol for fluorine-18 fluorodeoxyglucose cardiac single-photon emission tomography. Eur J Nucl Med. 1997;24:1291–1297
  28. Cremerius U, Effert PJ, Adam G, et al.  FDG PET for detection and therapy control of metastatic germ cell tumour. J Nucl Med. 1999;39:815–822
  29. Ryu JS, Choi NC, Fischman AJ, et al.  FDG-PET in staging and restaging non-small cell lung cancer after neoadjuvant chemoradiotherapy (correlation with histopathology). Lung Cancer. 2002;35:179–187
  30. Dehdashti F, Flanagan FL, Mortimer JE, et al.  Positron emission tomographic assessment of “metabolic flare” to predict response of metastatic breast cancer to antiestrogen therapy. Eur J Nucl Med. 1999;26:51–56
  31. De Witte O, Hildebrand J, Luxen A, et al.  Acute effect of carmustine on glucose metabolism in brain and glioblastoma. Cancer. 1994;74:2836–2842
  32. Young H, Baum R, Cremerius U, et al.  Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography (review and 1999 EORTC recommendationsEuropean Organization for Research and Treatment of Cancer (EORTC) PET Study Group). Eur J Cancer. 1999;35:1773–1782
  33. Barrington SF, O’Doherty MJ. Limitations of PET for imaging lymphoma. Eur J Nucl Med. 2003;30:S117–S127
  34. Romer W, Hanauske AR, Ziegler S, et al.  Positron emission tomography in non-Hodgkin’s lymphoma (assessment of chemotherapy with fluorodeoxyglucose). Blood. 1998;91:4464–4471
  35. Findlay M, Young H, Cunningham D, et al.  Noninvasive monitoring of tumor metabolism using fluorodeoxyglucose and positron emission tomography in colorectal cancer liver metastases (correlation with tumor response to fluorouracil). J Clin Oncol. 1996;14:700–708
  36. Haberkorn U, Strauss LG, Dimitrakopoulou A, et al.  PET studies of fluorodeoxyglucose metabolism in patients with recurrent colorectal tumors receiving radiotherapy. J Nucl Med. 1991;32:1485–1490
  37. Greven KM, Williams DW, McGuirt WF, et al.  Serial positron emission tomography scans following radiation therapy of patients with head and neck cancer. Head Neck. 2001;23:942–946
  38. Goerres GW, Kamel E, Seifert B, et al.  Accuracy of image coregistration of pulmonary lesions in patients with non-small cell lung cancer using an integrated PET/CT system. J Nucl Med. 2002;43:1469–1475
  39. Goerres GW, Kamel E, Heidelberg TN, et al.  PET-CT image co-registration in the thorax (influence of respiration). Eur J Nucl Med. 2002;29:351–360
  40. Goerres GW, Burger C, Schwitter MR, et al.  PET/CT of the abdomen (optimizing the patient breathing pattern). Eur Radiol. 2003;13:734–739
  41. Osman MM, Cohade C, Nakamoto Y, et al.  Clinically significant inaccurate localization of lesions with PET/CT (frequency in 300 patients). J Nucl Med. 2003;44:240–243
  42. Dizendorf E, Hany TF, Buck A, et al.  Cause and magnitude of the error induced by oral CT contrast agent in CT-based attenuation correction of PET emission studies. J Nucl Med. 2003;44:732–738
  43. Goerres GW, Hany TF, Kamel E, et al.  Head and neck imaging with PET and PET/CT (artefacts from dental metallic implants). Eur J Nucl Med. 2002;29:367–370
  44. Kamel EM, Burger C, Buck A, von Schulthess GK, Goerres GW. Impact of metallic dental implants on CT-based attenuation correction in a combined PET/CT scanner. Eur Radiol. 2003;13:724–728
  45. Antoch G, Freudenberg LS, Egelhof T, et al.  Focal tracer uptake (a potential artifact in contrast-enhanced dual-modality PET/CT scans). J Nucl Med. 2002;43:1339–1342
  46. Cohade C, Wahl RL. Applications of PET/CT image fusion in clinical PET—Clinical use, interpretation methods, diagnostic improvements. Semin Nucl Med. 2003;33:228–237
  47. Goerres GW, Ziegler SI, Burger C, et al.  Artifacts at PET and PET/CT caused by metallic hip prosthetic material. Radiology. 2003;226:577–584
  48. Kinahan PE, Hasegawa BH, Beyer T. X-ray based attenuation correction for PET/CT scanners. Semin Nucl Med. 2003;33:166–179
  49. Hany TF, Steinert HC, Goerres GW, et al.  PET diagnostic accuracy: improvement with in-line PET-CT system: initial results. Radiology. 2002;225:575–581
  50. Cohen MS, Arslan N, Dehdashti F, et al.  Risk of malignancy in thyroid incidentalomas identified by fluorodeoxyglucose-positron emission tomography. Surgery. 2001;130:941–946
  51. Kamel EM, Goerres GW, Burger C, et al.  Recurrent laryngeal nerve palsy in patients with lung cancer (detection with PET-CT image fusion—report of six cases). Radiology. 2002;224:153–156
  52. Mayer D, Bednarczyk EM. Interaction of colony-stimulating factors and fluorodeoxyglucose positron emission tomography. Ann Pharmacother. 2002;36:1796–1799
  53. Shon IH, Fogelman I. F-18 FDG positron emission tomography and benign fractures. Clin Nucl Med. 2003;28:171–175
  54. Zhuang HM, Feng Q, Chacho TK, et al.  Rapid normalization of FDG uptake of skeletal structure following fractures and surgical interventions. J Nucl Med. 2002;43:38P
  55. Cook GJ, Maisey MN, Fogelman I. Fluorine-18-FDG PET in Paget’s disease of bone. J Nucl Med. 1997;38:1495–1497
  56. Dehdashti F, Siegel BA, Griffeth LK, et al.  Benign versus malignant intraosseous lesions (discrimination by means of PET with 2-[F-18]fluoro-2-deoxy-D-glucose). Radiology. 1996;200:243–247
  57. Kalicke T, Schmitz A, Risse JH, et al.  Fluorine-18 fluorodeoxyglucose PET in infectious bone diseases (results of histologically confirmed cases). Eur J Nucl Med. 2000;27:524–528
  58. Zhuang H, Alavi A. 18-fluorodeoxyglucose positron emission tomographic imaging in the detection and monitoring of infection and inflammation. Semin Nucl Med. 2002;32:47–59
  59. Horiuchi M, Yasuda S, Shohtsu A, et al.  Four cases of Warthin’s tumor of the parotid gland detected with FDG PET. Ann Nucl Med. 1998;12:47–50
  60. Yasuda S, Fujii H, Nakahara T, et al.  18F-FDG PET detection of colonic adenomas. J Nucl Med. 2001;42:989–992
  61. Dobert N, Menzel C, Ludwig R, et al.  Enchondroma (a benign osseous lesion with high F-18 FDG uptake). Clin Nucl Med. 2002;27:695–697
  62. Adams S, Baum R, Rink T, et al.  Limited value of fluorine-18 fluorodeoxyglucose positron emission tomography for the imaging of neuroendocrine tumours. Eur J Nucl Med. 1998;25:79–83
  63. Cook GJ, Houston S, Rubens R, et al.  Detection of bone metastases in breast cancer by 18FDG PET (differing metabolic activity in osteoblastic and osteolytic lesions). J Clin Oncol. 1998;16:3375–3379
  64. Larcos G, Maisey MN. FDG-PET screening for cerebral metastases in patients with suspected malignancy. Nucl Med Commun. 1996;17:197–198

PII: S0001-2998(03)00105-3

doi: 10.1053/j.semnuclmed.2003.12.003

Seminars in Nuclear Medicine
Volume 34, Issue 2 , Pages 122-133 , April 2004

Article Tools

* Image Usage & Resolution